{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(4)"],"submitter":["Guedj K"],"pubmed_abstract":["<h4>Background</h4>Severe acute respiratory syndrome caused by the novel coronavirus (SARS-CoV-2) is frequently associated with gastrointestinal manifestations. Herein we evaluated the interest in measuring the intestinal fatty acid-binding protein (I-FABP), a biomarker of intestinal injury, in COVID-19 patients.<h4>Methods</h4>Serum I-FABP was analyzed in 28 consecutive patients hospitalized for a PCR-confirmed COVID-19, in 24 hospitalized patients with non-COVID-19 pulmonary diseases, and 79 patients admitted to the emergency room for abdominal pain.<h4>Results</h4>I-FABP serum concentrations were significantly lower in patients with COVID-19, as compared to patients with non-COVID-19 pulmonary diseases [70.3 pg/mL (47-167.9) vs. 161.1 pg/mL (88.98-305.2), respectively, p = 0.008]. I-FABP concentrations in these two populations were significantly lower than in patients with abdominal pain without COVID-19 [344.8 pg/mL (268.9-579.6)]. I-FABP was neither associated with severity nor the duration of symptoms. I-FABP was correlated with polymorphonuclear cell counts.<h4>Conclusions</h4>In this pilot study, we observed a low I-FABP concentration in COVID-19 patients either with or without gastrointestinal symptoms, of which the pathophysiological mechanisms and clinical impact remain to be established. Further explorations on a larger cohort of patients will be needed to unravel the molecular mechanism of such observation, including the effects of malabsorption and/or abnormal lipid metabolism."],"journal":["PloS one"],"pagination":["e0249799"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8049236"],"repository":["biostudies-literature"],"pubmed_title":["I-FABP is decreased in COVID-19 patients, independently of the prognosis."],"pmcid":["PMC8049236"],"pubmed_authors":["Nicoletti A","Corcos O","Trichet C","Nuzzo A","Weiss E","Peoc'h K","Guedj K","Soudan D","Manceau H","Uzzan M","Treton X"],"additional_accession":[]},"is_claimable":false,"name":"I-FABP is decreased in COVID-19 patients, independently of the prognosis.","description":"<h4>Background</h4>Severe acute respiratory syndrome caused by the novel coronavirus (SARS-CoV-2) is frequently associated with gastrointestinal manifestations. Herein we evaluated the interest in measuring the intestinal fatty acid-binding protein (I-FABP), a biomarker of intestinal injury, in COVID-19 patients.<h4>Methods</h4>Serum I-FABP was analyzed in 28 consecutive patients hospitalized for a PCR-confirmed COVID-19, in 24 hospitalized patients with non-COVID-19 pulmonary diseases, and 79 patients admitted to the emergency room for abdominal pain.<h4>Results</h4>I-FABP serum concentrations were significantly lower in patients with COVID-19, as compared to patients with non-COVID-19 pulmonary diseases [70.3 pg/mL (47-167.9) vs. 161.1 pg/mL (88.98-305.2), respectively, p = 0.008]. I-FABP concentrations in these two populations were significantly lower than in patients with abdominal pain without COVID-19 [344.8 pg/mL (268.9-579.6)]. I-FABP was neither associated with severity nor the duration of symptoms. I-FABP was correlated with polymorphonuclear cell counts.<h4>Conclusions</h4>In this pilot study, we observed a low I-FABP concentration in COVID-19 patients either with or without gastrointestinal symptoms, of which the pathophysiological mechanisms and clinical impact remain to be established. Further explorations on a larger cohort of patients will be needed to unravel the molecular mechanism of such observation, including the effects of malabsorption and/or abnormal lipid metabolism.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2024-02-15T07:08:24.334Z","creation":"2022-02-09T15:54:32.938Z"},"accession":"S-EPMC8049236","cross_references":{"pubmed":["33857216"],"doi":["10.1371/journal.pone.0249799"]}}